Zacks Research Issues Positive Forecast for BMRN Earnings
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) – Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a research note issued on Wednesday, March 12th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $0.69 per share for the quarter, up […]
